SG11201810366WA - 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides - Google Patents
3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamidesInfo
- Publication number
- SG11201810366WA SG11201810366WA SG11201810366WA SG11201810366WA SG11201810366WA SG 11201810366W A SG11201810366W A SG 11201810366WA SG 11201810366W A SG11201810366W A SG 11201810366WA SG 11201810366W A SG11201810366W A SG 11201810366WA SG 11201810366W A SG11201810366W A SG 11201810366WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- berlin
- pct
- compounds
- co7d
- Prior art date
Links
- MOVDLRJXICFWKP-UHFFFAOYSA-N 3-oxo-2,6-diphenylpyridazine-4-carboxamide Chemical class O=C1N(N=C(C=C1C(=O)N)C1=CC=CC=C1)C1=CC=CC=C1 MOVDLRJXICFWKP-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
- C07D237/16—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111101111 0 DOI 010111110101111 0 01010 1101 OH HI 111110 lil OE lil Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\"\"\") WO 2017/202816 Al 30 November 2017 (30.11.2017) WIPO I PCT (51) International Patent Classification: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, CO7D 237/16 (2006.01) CO7D 405/12 (2006.01) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, CO7D 237/20 (2006.01) A61P 35/00 (2006.01) TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. C07D 403/12 (2006.01) A61K 31/501 (2006.01) (84) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of regional protection available): ARIPO (BW, GH, PCT/EP2017/062355 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (22) International Filing Date: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 23 May 2017 (23.05.2017) TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (25) Filing Language: English MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (26) Publication Language: English TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (30) Priority Data: PCT/CN2016/083308 Declarations under Rule 4.17: 25 May 2016 (25.05.2016) CN — as to applicant's entitlement to apply for and be granted a PCT/CN2017/074408 patent (Rule 4.17(0 22 February 2017 (22.02.2017) CN Published: (71) Applicants: BAYER PHARMA AKTIENGESEL- — with international search report (Art. 21(3)) LSCHAFT [DE/DE]; MilllerstraBe 178, 13353 Berlin (DE). DEUTSCHES KREBSFORSCHUNGSZEN- TRUM (DKFZ) [DE/DE]; Im Neuenheimer Feld 280, 69120 Heidelberg (DE). (72) Inventors: SCHMEES, Norbert; Bondickstr.61, 13469 Berlin (DE). GUTCHER, Ilona; Paul-Robeson-Str. 28, 10439 Berlin (DE). IRLBACHER, Horst; Winsstrasse 47, 10405 Berlin (DE). BADER, Benjamin; Hillmannstr. 14, 13467 Berlin (DE). ZHAO, Na; Nanhai Community, Shan- haizi east Road, BDA, Beijng, 100076 (CN). PLATTEN, Michael; Cambridgestr. 7, 69115 Heidelberg (DE). (74) Agent: BIP PATENTS; Alfred-Nobel-Str. 10, 40789 Mon- heim am Rhein (DE). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, = (81) (54) Title: 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES (57) : The present invention covers 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carbox- RS compounds of general formula (I): in which R1, R2, R3, R4, R5 and R6 are as defined here- R 4 R 6 pounds, pharmaceutical compositions and combinations comprising said compounds and the use of go in, methods of preparing said compounds, intermediate compounds useful for preparing said com- said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis 1-1 GC of diseases, in particular of cancer or conditions with 10 dysregulated immune responses or other N N' disorders associated with aberrant AHR signaling, as a sole agent or in combination with other ac- 0 ei /0 tive ingredients. IN Il 14111 H N. R 1 0 ei (I) O
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016083308 | 2016-05-25 | ||
| CN2017074408 | 2017-02-22 | ||
| PCT/EP2017/062355 WO2017202816A1 (en) | 2016-05-25 | 2017-05-23 | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810366WA true SG11201810366WA (en) | 2018-12-28 |
Family
ID=58745251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810366WA SG11201810366WA (en) | 2016-05-25 | 2017-05-23 | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US11040035B2 (en) |
| EP (1) | EP3464248B1 (en) |
| JP (1) | JP6964096B2 (en) |
| KR (1) | KR20190009369A (en) |
| CN (1) | CN109863140B (en) |
| AU (1) | AU2017269870A1 (en) |
| BR (1) | BR112018074185A2 (en) |
| CA (1) | CA3025227A1 (en) |
| CL (1) | CL2018003345A1 (en) |
| CO (1) | CO2018012654A2 (en) |
| CR (1) | CR20180556A (en) |
| CU (1) | CU20180143A7 (en) |
| DO (1) | DOP2018000256A (en) |
| EA (1) | EA201892666A1 (en) |
| EC (1) | ECSP18087725A (en) |
| IL (1) | IL263046A (en) |
| MA (1) | MA45087A (en) |
| MX (1) | MX2018014443A (en) |
| NI (1) | NI201800124A (en) |
| PE (1) | PE20190509A1 (en) |
| PH (1) | PH12018502472A1 (en) |
| SG (1) | SG11201810366WA (en) |
| SV (1) | SV2018005787A (en) |
| TN (1) | TN2018000392A1 (en) |
| TW (1) | TW201742859A (en) |
| UY (1) | UY37256A (en) |
| WO (1) | WO2017202816A1 (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI759301B (en) | 2016-05-24 | 2022-04-01 | 美商安美基公司 | Pegylated carfilzomib compounds |
| JOP20190193A1 (en) * | 2017-02-09 | 2019-08-08 | Bayer Pharma AG | Heterocyclic 2-aryl-3-oxo-2,3-dihydroepyridazine-4-carboxamide for treating cancer |
| US11459312B2 (en) | 2017-11-21 | 2022-10-04 | Bayer Aktiengesellschaft | Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides |
| EA037978B1 (en) * | 2017-11-21 | 2021-06-18 | Байер Акциенгезельшафт | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer |
| WO2019101647A1 (en) * | 2017-11-21 | 2019-05-31 | Bayer Aktiengesellschaft | 2-phenylpyrimidine-4-carboxamides as ahr inhibitors |
| US11591311B2 (en) | 2017-11-21 | 2023-02-28 | Bayer Aktiengesellschaft | 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides |
| EP3841102B1 (en) | 2018-08-24 | 2022-09-14 | Jaguahr Therapeutics Pte Ltd | Tetrahydropyridopyrimidine derivatives as ahr modulators |
| EP3843853A1 (en) | 2018-08-31 | 2021-07-07 | Jaguahr Therapeutics Pte Ltd | Heterocyclic compounds as ahr modulators |
| CN109771437B (en) * | 2019-03-28 | 2023-03-17 | 西安交通大学医学院第一附属医院 | Application of trifluorothymidine in preparing medicine for treating triple negative breast cancer |
| EP3715471A1 (en) * | 2019-03-29 | 2020-09-30 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Ahr signature marker set |
| EP3721894A1 (en) | 2019-04-10 | 2020-10-14 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Interleukin-4-induced gene 1 (il4i1) as a biomarker and uses thereof |
| WO2021020362A1 (en) * | 2019-07-29 | 2021-02-04 | 武田薬品工業株式会社 | Heterocyclic compound |
| EP3835432A1 (en) | 2019-12-10 | 2021-06-16 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Interleukin-4-induced gene 1 (il4i1) and respective metabolites as biomarkers for cancer |
| KR20220128622A (en) * | 2019-12-16 | 2022-09-21 | 바이엘 악티엔게젤샤프트 | Combinations of AHR-inhibitors and PD1-inhibitor antibodies and their use in the treatment of cancer |
| JP2023510797A (en) | 2020-01-10 | 2023-03-15 | イケナ オンコロジー， インコーポレイテッド | AHR inhibitors and uses thereof |
| JP2023515128A (en) | 2020-02-26 | 2023-04-12 | ジャガー セラピューティクス ピーティーイーリミテッド | Pyridopyrimidine Derivatives Useful for Modulating AHR Signaling |
| KR20230005844A (en) * | 2020-03-27 | 2023-01-10 | 동아에스티 주식회사 | Aminopyrimidine derivatives and their use as aryl hydrocarbon receptor modulators |
| US11911376B2 (en) | 2020-03-30 | 2024-02-27 | The Regents Of The University Of Colorado | Methods for preventing and treating retinal damage |
| CN114181212B (en) * | 2020-09-15 | 2023-06-06 | 山东轩竹医药科技有限公司 | Pyridazinone AhR inhibitors |
| CN114369097B (en) * | 2020-10-15 | 2023-07-14 | 山东轩竹医药科技有限公司 | Heteroaromatic AhR inhibitors |
| CN114685426A (en) * | 2020-12-28 | 2022-07-01 | 苏州泽璟生物制药股份有限公司 | Sulfonamide inhibitor and preparation method and application thereof |
| JP2024535019A (en) * | 2021-09-14 | 2024-09-26 | アライアンテラ（スーヂョウ）バイオファーマシューティカル・カンパニー・リミテッド | 2-aryl or heteroaryl-3-oxo-4-carbamido-6-cyclic-dihydropyrazine aryl hydrocarbon receptor modulators and their use in treating diseases and disorders - Patents.com |
| EP4598931A1 (en) | 2022-10-03 | 2025-08-13 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
| WO2025114771A1 (en) | 2023-11-29 | 2025-06-05 | Latvian Institute Of Organic Synthesis | A new class of aryl hydrocarbon receptor antagonists and their optimisation |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4134467A1 (en) | 1991-10-18 | 1993-04-22 | Thomae Gmbh Dr K | HETEROBIARYL DERIVATIVES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF |
| KR100657189B1 (en) * | 1998-08-14 | 2006-12-14 | 니혼노야쿠가부시키가이샤 | Pyridazinone derivatives and pharmaceutical compositions containing the same |
| NZ524745A (en) * | 2000-09-18 | 2006-01-27 | Eisai Co Ltd | Pyridazinones and triazinones and medicinal use thereof |
| FR2847253B1 (en) * | 2002-11-19 | 2007-05-18 | Aventis Pharma Sa | NOVEL DERIVATIVES OF PYRIDAZINONES AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM |
| FR2847235B1 (en) | 2002-11-20 | 2005-07-08 | Essilor Int | PROTECTIVE AND SETTING PACKAGING FOR CIRCULAR CONTOUR OBJECTS |
| EP1953147A1 (en) | 2005-11-21 | 2008-08-06 | Japan Tobacco, Inc. | Heterocyclic compound and medicinal application thereof |
| WO2009142732A2 (en) | 2008-05-20 | 2009-11-26 | Cephalon, Inc. | Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands |
| PE20100362A1 (en) | 2008-10-30 | 2010-05-27 | Irm Llc | PURINE DERIVATIVES THAT EXPAND HEMATOPOYETIC STEM CELLS |
| WO2012015914A2 (en) | 2010-07-27 | 2012-02-02 | Trustees Of Boston University | Aryl hydrocarbon receptor (ahr) modifiers as novel cancer therapeutics |
| US20170173008A1 (en) * | 2014-03-19 | 2017-06-22 | President And Fellows Of Harvard College | Antimicrobial agents and screening methods |
| JOP20190193A1 (en) * | 2017-02-09 | 2019-08-08 | Bayer Pharma AG | Heterocyclic 2-aryl-3-oxo-2,3-dihydroepyridazine-4-carboxamide for treating cancer |
-
2017
- 2017-05-23 SG SG11201810366WA patent/SG11201810366WA/en unknown
- 2017-05-23 BR BR112018074185-0A patent/BR112018074185A2/en not_active IP Right Cessation
- 2017-05-23 CR CR20180556A patent/CR20180556A/en unknown
- 2017-05-23 EP EP17724833.3A patent/EP3464248B1/en active Active
- 2017-05-23 KR KR1020187037050A patent/KR20190009369A/en not_active Ceased
- 2017-05-23 WO PCT/EP2017/062355 patent/WO2017202816A1/en active Application Filing
- 2017-05-23 AU AU2017269870A patent/AU2017269870A1/en not_active Abandoned
- 2017-05-23 CU CU2018000143A patent/CU20180143A7/en unknown
- 2017-05-23 JP JP2018561224A patent/JP6964096B2/en active Active
- 2017-05-23 CN CN201780046149.5A patent/CN109863140B/en active Active
- 2017-05-23 CA CA3025227A patent/CA3025227A1/en active Pending
- 2017-05-23 PE PE2018003109A patent/PE20190509A1/en unknown
- 2017-05-23 US US16/303,539 patent/US11040035B2/en active Active
- 2017-05-23 TN TNP/2018/000392A patent/TN2018000392A1/en unknown
- 2017-05-23 MA MA045087A patent/MA45087A/en unknown
- 2017-05-23 MX MX2018014443A patent/MX2018014443A/en unknown
- 2017-05-23 EA EA201892666A patent/EA201892666A1/en unknown
- 2017-05-24 UY UY0001037256A patent/UY37256A/en not_active Application Discontinuation
- 2017-05-25 TW TW106117299A patent/TW201742859A/en unknown
-
2018
- 2018-11-15 IL IL263046A patent/IL263046A/en unknown
- 2018-11-23 SV SV2018005787A patent/SV2018005787A/en unknown
- 2018-11-23 CL CL2018003345A patent/CL2018003345A1/en unknown
- 2018-11-23 NI NI201800124A patent/NI201800124A/en unknown
- 2018-11-23 PH PH12018502472A patent/PH12018502472A1/en unknown
- 2018-11-23 CO CONC2018/0012654A patent/CO2018012654A2/en unknown
- 2018-11-23 EC ECSENADI201887725A patent/ECSP18087725A/en unknown
- 2018-11-23 DO DO2018000256A patent/DOP2018000256A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TN2018000392A1 (en) | 2020-06-15 |
| US11040035B2 (en) | 2021-06-22 |
| US20200237757A1 (en) | 2020-07-30 |
| EP3464248B1 (en) | 2021-09-08 |
| UY37256A (en) | 2018-01-02 |
| SV2018005787A (en) | 2019-02-07 |
| KR20190009369A (en) | 2019-01-28 |
| CL2018003345A1 (en) | 2019-03-15 |
| CR20180556A (en) | 2019-04-23 |
| BR112018074185A2 (en) | 2019-03-06 |
| DOP2018000256A (en) | 2019-02-15 |
| CU20180143A7 (en) | 2019-07-04 |
| PE20190509A1 (en) | 2019-04-10 |
| EA201892666A1 (en) | 2019-08-30 |
| ECSP18087725A (en) | 2018-11-30 |
| WO2017202816A1 (en) | 2017-11-30 |
| EP3464248A1 (en) | 2019-04-10 |
| MA45087A (en) | 2021-05-26 |
| JP2019516744A (en) | 2019-06-20 |
| CN109863140A (en) | 2019-06-07 |
| IL263046A (en) | 2018-12-31 |
| NI201800124A (en) | 2019-04-29 |
| CA3025227A1 (en) | 2017-11-30 |
| CO2018012654A2 (en) | 2018-12-14 |
| TW201742859A (en) | 2017-12-16 |
| AU2017269870A1 (en) | 2018-12-06 |
| JP6964096B2 (en) | 2021-11-10 |
| MX2018014443A (en) | 2019-04-15 |
| PH12018502472A1 (en) | 2019-09-23 |
| CN109863140B (en) | 2023-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810366WA (en) | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides | |
| SG11201907232XA (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| SG11202000266VA (en) | Quinoline derivatives for treating infections with helminths | |
| SG11201809132RA (en) | Novel compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201903059SA (en) | New anthelmintic quinoline-3-carboxamide derivatives | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201809126RA (en) | Aromatic sulfonamide derivatives | |
| SG11201807540UA (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201903892UA (en) | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors | |
| SG11201901374WA (en) | Antibiotic compounds | |
| SG11201902531QA (en) | Liquid pharmaceutical composition | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201809469QA (en) | [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl] (1h-1,2,3-triazol-4-yl)methanones | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201811221XA (en) | Imidazo[1,2-a]pyridine derivatives, methods for preparing the same and use thereof | |
| SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
| SG11201909735YA (en) | Therapeutic compounds and compositions, and methods of use thereof | |
| SG11201903770UA (en) | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders | |
| SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch |